Medicines containing Andrographis paniculata
(Andrographis), a commonly used over-the-counter herbal ingredient, are no
longer eligible to be listed on the Australian Register of Therapeutic Goods
(ARTG). All listed medicines containing Andrographis have been withdrawn or
recalled.1
Andrographis-containing products have been commonly used for the
prevention and management of ‘cold and flu’. The decision to remove
Andrographis from Australia’s list of permissible ingredients follows an updated safety review from the Therapeutic Goods Administration (TGA) that found an unacceptable risk of allergic
reactions including anaphylaxis.2 The TGA had received 287 reports of
anaphylaxis linked to medicines containing Andrographis up to the end of 2025,
including a fatal case reported in June 2024. They also received approximately
600 reports of ageusia or dysgeusia (loss or distortion of the sense of
taste).2
The TGA safety review stated that concerns about
life-threatening reactions from Andrographis are magnified by their
unpredictable nature, with anaphylactic reactions occurring on first exposure
or on later exposures following previous use without a reaction.2
Risk mitigation strategies such as strengthened label warnings and
public education were considered insufficient to manage this risk.2
Listed medicines are generally lower-risk products, and the TGA decided that
the risk of severe allergic reactions associated with Andrographis was not
consistent with this classification. Andrographis-containing medicines will now
be regulated via the registered medicines pathway, which means a sponsor would
need to submit evidence of efficacy and safety to have the product registered
on the ARTG.
The delisting of Andrographis illustrates the benefits of
adverse drug reaction reporting because without adverse event reports the risk of
harm associated with this drug may not have been identified. Adverse events to
any drug, including herbal medicines, can be reported online by health
professionals or consumers at the TGA adverse event reporting webpage.
Australian Prescriber welcomes Feedback.